‘1104 SC and SL dosing options create opportunities for highly differentiated product profiles in eosinophilic esophagitis (EoE) and other allergic diseases versus currently available therapies Data ...
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced its decision to accelerate the advancement of a sublingual, ...
Dr. De Alba will discuss preclinical studies that show the potential of the Company’s lead clinical asset, ‘1104, for treating atopic dermatitis (AD). In a chronic allergen-driven murine model of AD, ...
In multiple preclinical models evaluated in single-dose toxicity studies, there were no ‘1104-related local tolerability adverse effects after treatment with the ‘1104 SQ formulation at dose levels ...
NEW ORLEANS and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term ...
NEW ORLEANS and CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve ...
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve ...
- New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) - NEW ORLEANS and CAMBRIDGE, United Kingdom, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics ...
(MENAFN- GlobeNewsWire - Nasdaq) '1104 sublingual formulation achieved extensive systemic exposure and demonstrated impact across measures of disease in additional preclinical studies in atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback